(Q45298284)

11 December 2017

title

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice (English)

1 reference

11 December 2017

0 references

9

Robert J Ferrante

1 reference

11 December 2017

8

Steven M Hersch

1 reference

11 December 2017

Edward C Stack

1

1 reference

11 December 2017

James K Kubilus

2

1 reference

11 December 2017

Karen Smith

3

1 reference

11 December 2017

Kerry Cormier

4

1 reference

11 December 2017

Steven J Del Signore

5

1 reference

11 December 2017

Emmanuel Guelin

6

1 reference

11 December 2017

Hoon Ryu

7

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

The Journal of Comparative Neurology

11 December 2017

published in

1 reference

11 December 2017

volume

490

1 reference

11 December 2017

issue

4

1 reference

11 December 2017

page(s)

354-370

1 reference

Weight loss in early stage of Huntington's disease

11 December 2017

cites work

1 reference

Huntington's disease: clinical correlates of disability and progression

21 January 2018

1 reference

Emerging chemotherapeutic strategies for Huntington's disease

21 January 2018

1 reference

Postural stability in patients with Huntington's disease

21 January 2018

1 reference

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

21 January 2018

1 reference

7 January 2021

Experimental therapeutics in transgenic mouse models of Huntington's disease

1 reference

7 January 2021

Evidence for a disorder of locomotor timing in Huntington's disease

1 reference

7 January 2021

Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice

1 reference

7 January 2021

The intrinsically unstable life of DNA triplet repeats associated with human hereditary disorders

1 reference

7 January 2021

Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

1 reference

7 January 2021

Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene

1 reference

7 January 2021

Transcriptional dysregulation in Huntington's disease

1 reference

7 January 2021

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease

1 reference

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

7 January 2021

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

1 reference

7 January 2021

Therapeutic effects of cystamine in a murine model of Huntington's disease.

1 reference

7 January 2021

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

1 reference

7 January 2021

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

1 reference

7 January 2021

Disturbances of precision grip in Huntington's disease

1 reference

7 January 2021

Selective sparing of a class of striatal neurons in Huntington's disease

1 reference

7 January 2021

Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum

1 reference

7 January 2021

Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease

1 reference

7 January 2021

Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry

1 reference

7 January 2021

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

7 January 2021

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

1 reference

7 January 2021

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

1 reference

7 January 2021

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

1 reference

7 January 2021

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice

1 reference

7 January 2021

Coordination of prehensile forces during precision grip in Huntington's disease.

1 reference

7 January 2021

Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease

1 reference

7 January 2021

Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

1 reference

7 January 2021

Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers

1 reference

7 January 2021

Translating therapies for Huntington's disease from genetic animal models to clinical trials

1 reference

7 January 2021

The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease

1 reference

7 January 2021

Metabolic and glutamatergic disturbances in the Huntington's disease transgenic mouse.

1 reference

7 January 2021

Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype

1 reference

7 January 2021

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

7 January 2021

Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease.

1 reference

7 January 2021

Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene

1 reference

7 January 2021

Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?

1 reference

7 January 2021

Progression of symptoms in the early and middle stages of Huntington disease

1 reference

7 January 2021

Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene

1 reference

7 January 2021

Trinucleotide repeat expansion in neurological disease

1 reference

7 January 2021

Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease

1 reference

7 January 2021

Evidence for specific cognitive deficits in preclinical Huntington's disease.

1 reference

7 January 2021

Huntingtin and its role in neuronal degeneration

1 reference

7 January 2021

Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice

1 reference

7 January 2021

Neurological abnormalities in a knock-in mouse model of Huntington's disease

1 reference

7 January 2021

Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus

1 reference

7 January 2021

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

1 reference

7 January 2021

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

1 reference

7 January 2021

Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice

1 reference

7 January 2021

Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice

1 reference

7 January 2021

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats

1 reference

7 January 2021

Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity

1 reference

7 January 2021

Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation

1 reference

7 January 2021

Clinical and neuropathologic assessment of severity in Huntington's disease

1 reference

7 January 2021

Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity

1 reference

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

7 January 2021

Functional brain changes in presymptomatic Huntington's disease

1 reference

7 January 2021

Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.

1 reference

7 January 2021

Recent advances in understanding the pathogenesis of Huntington's disease

1 reference

7 January 2021

Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

1 reference

7 January 2021

Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease

1 reference

7 January 2021

Protein aggregation and neurodegenerative disease

1 reference

7 January 2021

Polyglutamine pathogenesis.

1 reference

7 January 2021

Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?

1 reference

7 January 2021

The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease

1 reference

7 January 2021

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

1 reference

7 January 2021

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

1 reference

7 January 2021

A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice

1 reference

7 January 2021

Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease

1 reference

7 January 2021

Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport

1 reference

7 January 2021

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro

1 reference

7 January 2021

Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease

1 reference

7 January 2021

Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice

1 reference

7 January 2021

Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion

1 reference

7 January 2021

Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation

1 reference

7 January 2021

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

1 reference

7 January 2021

Depletion of wild-type huntingtin in mouse models of neurologic diseases

1 reference

7 January 2021

Identifiers

DOI

10.1002/CNE.20680

1 reference

11 December 2017

1 reference